Table 1 Correlation between the expression of lncRNA OIP5-AS1 in multiple myeloma patients and clinicopathological characteristics

Age (years)

0.2970

 ≥ 61

20

0.65 ± 0.06

 < 61

18

0.62 ± 0.11

Sex

0.6432

 Man

18

0.63 ± 0.08

 Woman

20

0.64 ± 0.05

Type of monoclonal immunoglobulin

0.5162

 IgG

18

0.66 ± 0.06

 IgA

12

0.64 ± 0.05

 IgD

3

0.61 ± 0.12

 Light chain only

5

0.63 ± 0.04

Peripheral blood cell count

 WBC, × 109/L

0.3214

  < 5.40

19

0.58 ± 0.08

  ≥ 5.40

19

0.67 ± 0.11

 Hb, g/L

  < 83.5

19

0.62 ± 0.07

0.5879

  ≥ 83.5

19

0.63 ± 0.03

 PLT, × 109/L

  < 127

19

0.64 ± 0.09

0.5213

  ≥ 127

19

0.61 ± 0.06

 ISS stage

< 0.001***

  I

8

1.03 ± 0.08

  II

14

0.71 ± 0.04

  III

16

0.43 ± 0.09

 IMWG risk stratification

< 0.001***

  Low risk

7

1.2 ± 0.05

  Intermediate risk

19

0.68 ± 0.12

  High risk

12

0.59 ± 0.08